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ABSTRACT 
Background: Hunger hormone levels are typically dysregulated in obese and diabetic 
populations, however; postprandial exercise has been shown to influence hunger hormone levels.   
Purpose: To determine if hunger hormones including acylated ghrelin and GLP-1 levels are 
altered in response to an acute bout (15 minutes) of walking in individuals at risk for type 2 
diabetes mellitus (T2DM).  
Methods: Ten subjects at risk for prediabetes (fasting blood glucose 100–125mg/dL) 
participated in this randomized crossover design trial. Subjects arrived at the laboratory 
following an overnight fast and underwent one of two conditions: 1) Test meal with no walking 
(CON) or 2) Test meal followed by a 15-minute treadmill walk at preferred walking speed 
(WALK). Blood samples were taken over two hours and assayed for acylated ghrelin and active 
GLP-1. A repeated measures ANOVA was used to compare mean differences for all outcome 
variables.  
Results: There were no statistical differences in acylated ghrelin (F = 1.535, p = 0.247) or GLP-1 
(F = 0.003, p = 0.955) concentrations between CON and WALK conditions at any time period. 
There was a main effect of time for ghrelin (F = 41.339; p < 0.001). Post hoc analysis indicated a 
significant difference between baseline and 60 minutes (p < 0.001) and between baseline and 120 
minutes (p < 0.001) for acylated ghrelin concentrations. No difference was found between 60 
minutes and 120 minutes (p = 0.834). There was a main effect of time for GLP-1 (F = 17.968; p 
< 0.001). Post hoc analysis indicated a significant difference between baseline and 60 minutes (p 
= 0.001) and between baseline and 120 minutes (p = 0.002) for GLP-1 concentrations. No 
difference was found between 60 minutes and 120 minutes (p = 0.665). There was no significant 
difference in the AUC for acylated ghrelin between the CON and WALK conditions (t = -1.257; 
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p = 0.240). There was no significant difference in the AUC for GLP-1 between the CON and 
WALK conditions (t = -0.107; p = 0.918). Correlations between perceived hunger and biological 
hunger were weak and nonsignificant (p > 0.05). 
Conclusion: A 15-minute walk performed shortly after a meal does not have a significant impact 
on hunger hormones including acylated ghrelin and active GLP-1 concentrations in individuals at 
risk for T2DM.  
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CHAPTER 1: 
INTRODUCTION 
The prevalence of type 2 diabetes mellitus (T2DM) and impaired glucose regulation is 
increasing rapidly throughout the United States. Approximately, 415 million adults currently 
have diabetes and that number is estimated to rise to 642 million by 2040 [1]. T2DM is a major 
risk factor for end-stage renal disease, blindness, amputations, and coronary artery disease [2, 3]. 
In 2010, diabetes was the seventh leading cause of death in the United States with 69,071 death 
certificates listing it as the cause of death, plus a total of 234,051 death certificates listing 
diabetes as either an underlying or contributing cause of death [4]. A 2017 study suggests that 
diabetes prevalence may be higher than expected with 12% of American deaths related to 
diabetes, making it the third leading cause of death in 2010 [5]. The American Diabetes 
Association indicates that 1.4 million Americans are diagnosed with diabetes every year [4]. 
Consequently, the increased prevalence of T2DM has many direct and indirect financial burdens 
on healthcare costs. In 2012, the total costs of diagnosed diabetes in the United States was $245 
billion [6], which will continue to increase as the prevalence of T2DM is expected to rapidly rise. 
Therefore, identifying effective prevention strategies is crucial in combating the burden of 
T2DM and its complications.  
Prediabetes is defined as fasting blood glucose levels that are higher than normal (100–
125 mg/dL), but not high enough to reach the diabetic range (³ 126 mg/dL) [3]. There are 
currently three phenotypes of diabetes: impaired fasting glucose (IFG), impaired glucose 
tolerance (IGT), or a combination of both (IFG + IGT) [7]. Individuals with prediabetes are at a 
greater risk for developing T2DM and/or cardiovascular disease (CVD) [7, 8]. In 2012, 
approximately 86 million Americans had prediabetes, which is particularly concerning due to the 
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elevated risk for T2DM and CVD [7]. Many risk factors both hereditary and lifestyle-related are 
involved in contributing to the development of prediabetes and T2DM. A few risk factors 
include: being overweight (the primary risk factor); physical inactivity due to cells becoming less 
sensitive to insulin; and waist circumference, which ultimately can indicate insulin resistance [9].   
Hunger hormones are typically dysregulated in the diabetic population compared to 
healthy individuals [10]. The orexigenic hormone, ghrelin increases during periods of fasting and 
plays a role in the initiation of a meal [11]. Levels of ghrelin are suppressed after feeding, 
demonstrating its reaction to acute changes in nutritional state [12]. Simultaneously, 
anorexigenic hormones such as glucagon-like peptide-1 (GLP-1) play a role in satiety by being 
released into circulation following food ingestion [11]. Poykko et al. (2003) demonstrated that 
fasting plasma concentrations of total ghrelin were lower in subjects with T2DM compared to 
those without [13], while Adam et al. (2007) revealed that individuals with T2DM have blunted 
GLP-1 responses [14]. However, Shiiya et al. (2002) showed that there were no significant 
differences in plasma ghrelin concentrations between normal-weight healthy subjects and 
normal-weight T2DM subjects after a glucose injection [15]. There were no significant 
differences in plasma ghrelin concentrations between diabetic and nondiabetic groups in both 
lean and obese subjects. [15]. Attempts have been made to reverse the dysregulation of hunger 
hormones in the obese and diabetic populations. Therapies include infusion of satiety hormones 
[16, 17] or gastric procedures [12, 18] to mimic hormone levels of healthy nondiabetic 
individuals in overweight/obese adults. 
A principal prevention strategy for the management of T2DM includes exercise, either 
alone or in combination with other lifestyle modifications. Indeed, the favorable effects of 
exercise on glucose levels and insulin sensitivity have been well established [19, 20]. Exercise 
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not only improves glucose levels, but it also has a positive impact on hormonal markers related 
to appetite [21]. Wasse et al. (2013) demonstrated vigorous running and cycling suppresses 
acylated ghrelin concentrations in a fasted state when compared to a sedentary group [22]. 
Similar results were found by Broom et al. (2007, 2009) with the suppression of acylated ghrelin 
during 60-minute treadmill running at ~ 68% of maximal oxygen uptake (VO2max) and 72% 
VO2max compared to the sedentary control group in a fasted state [23, 24]. Unfortunately, these 
studies did not look at the diabetic population. Most current studies have looked at a single bout 
of high intensity exercise > 30 minutes and its effects on hormone concentrations [22, 24]. Very 
few investigations have looked at an acute bout of postprandial exercise in the diabetic 
population or a short, moderate-intensity bout of exercise and its effects on the hunger hormones. 
Deguchi et al. (2015) studied postprandial walking effects in type 2 diabetics. Natural 
walking, 10% fast walking, and 20% fast walking were compared. Only blood glucose measures 
were analyzed, which showed walking reduced postprandial blood glucose levels in an intensity-
dependent manner [25]. Ueda et al. (2009a) studied healthy male subjects cycling at different 
exercise intensities including 50% VO2max (moderate intensity) and 75% VO2max (high intensity) 
or resting for 30 minutes. Levels of GLP-1 increased during exercise and were similar between 
the two exercise groups showing that GLP-1 was positively impacted by exercise regardless of 
intensity [26]. Ueda et al. (2009b) also found that a 60-minute cycle at 50% VO2max resulted in a 
significant increase in GLP-1 concentrations in both healthy and obese subjects compared to the 
rest condition [27].   
The purpose of this study is to determine if a short, moderate-intensity bout of exercise at 
a self-selected walking pace, will be sufficient in decreasing acylated ghrelin levels and 
increasing GLP-1 levels compared to a resting control group in individuals at risk for T2DM.  
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Research Question 1: Will an acute bout of exercise further decrease acylated ghrelin levels in 
individuals at risk for T2DM? 
H0: There will be a significant decrease in acylated ghrelin postprandially in the exercise 
group compared to the control group 
H1: There will not be a significant decrease in acylated ghrelin postprandially in the exercise 
group compared to the control group 
Research Question 2: Will an acute bout of exercise further increase GLP-1 levels in individuals 
at risk for T2DM? 
H0: There will be a significant increase in GLP-1 postprandially in the exercise group 
compared to the control group 
H1: There will not be a significant increase in GLP-1 postprandially in the exercise group 
compared to the control group 
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CHAPTER 2: 
LITERATURE REVIEW 
Mechanisms in Regulating Hunger 
Energy Regulation  
Energy balance is a homeostatic system in which body weight is regulated by a complex 
system of peripheral and central factors. The main regions of the brain including the 
hypothalamus and brainstem, are responsible for the regulation of energy homeostasis through 
central factors. The peripheral factors, such as the gut, includes endocrine tissues that are also 
involved in the regulation of energy balance. Appetite regulation is controlled by anorexigenic 
and orexigenic gut hormones. These hormones interact with receptors located at various points 
along the ‘brain-gut axis’ to affect short-term and intermediate-term feelings of hunger and 
satiety. At the physiological and cellular level, the neuroendocrine system regulates both food 
intake and appetite [28]. 
The hypothalamus and brainstem receive neural and hormonal signals from the periphery 
to encode information regarding the acute nutritional state and adiposity [28]. Within the arcuate 
nucleus (ARC) of the hypothalamus, neuronal populations drive either orexigenic or 
anorexigenic responses. Neurons that express agouti-related peptide (AgRP) sense the metabolic 
needs of the body and orchestrate a state of hunger. Appropriate activation of these neuronal 
populations defines a regulatory system for energy balance. However, this system is influenced 
by multiple gut-derived peptides conveying temporary information regarding hunger and satiety 
throughout the transition from the fasted to the fed state. Leptin for example, is an adipose tissue-
derived hormone that delivers essential information to the hypothalamus regarding long-term 
energy stores [29]. 
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Brain-Gut Axis 
The brain-gut axis refers to the lines of communication between the gastrointestinal tract 
(GIT) and the central nervous system (CNS). Both neural and endocrine signaling from the gut 
play important roles in the regulation of short-term appetite, which forms a crucial component in 
appetite regulation [30]. The ARC in the hypothalamus and the dorsal vagal complex, located in 
the brain stem are the main regions of the brain particularly involved in controlling hunger and 
satiety [31, 32]. Both of these structures have extensive reciprocal connections in order to receive 
neuronal feedback from the periphery, in particular; the brainstem-vagus nerve complex is 
significant in the control of feeding [30]. The GIT contains mechanoreceptors and 
chemoreceptors to provide signals to the brainstem through the vagal nerve. These neural signals 
are centrally integrated with the signals conducted by the numerous hormones secreted from the 
GIT. The gut hormones then stimulate the vagal pathways from the gut to the brainstem, or they 
act directly on neurons in the brain [28].  
Within the ARC, there are two subsets of neurons that integrate signals and influence 
energy homeostasis. These neurons include the neuropeptide Y (NPY)/AgRP neurons and the 
pro-opiomelanocortin (POMC)/cocaine-and amphetamine-regulated transcript (CART) neurons 
[33]. Feeding behavior and energy expenditure are both affected by alterations in the release of 
these neuropeptides, which result in the maintenance of energy homeostasis [30]. NPY and 
AgRP neurons express orexigenic properties (stimulating hunger), while POMC and CART 
neurons express anorexigenic properties (suppressing hunger) [32, 33]. It is believed that ghrelin 
induces hunger by stimulating the NPY/AgRP neurons. Conversely, hormones such as insulin, 
leptin, GLP-1, and peptide tyrosine-tyrosine (PYY) are thought to decrease energy intake by 
inducing satiety [34].  
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Together, these hormones signals are assimilated within the ARC to influence energy 
expenditure, energy intake, and overall energy balance. The mechanisms in which hormones 
interact with CNS appetite centers are controversial. The proximity of the hypothalamus and 
brainstem to other structures with a comparative deficiency in the blood-brain barrier (BBB), 
could potentially allow circulating factors direct access to CNS neurons. Developing evidence 
suggests that the vagus nerve may be the primary site of action for some appetite-modulating 
hormones. Through targeting the interaction of appetite signals and their receptors within the 
vagal nerve, may offer the possible advantages for altering appetite at a site distant from the CNS 
[30]. 
Orexigenic Gut Hormones 
Ghrelin  
Ghrelin is a 28-amino acid peptide hormone including the addition of an octanoyl group 
[28]. It was originally isolated from the stomach as an endogenous-ligand for the growth 
hormone-secretagogue receptor (GHS-R), but ghrelin protein has been identified in additional 
peripheral tissues including the GIT, pancreas, and adrenal cortex [35]. The expression of ghrelin 
in these tissues suggests that it has both paracrine and autocrine functions [36, 37]. Ghrelin 
peptide is the first gut hormone proven to have orexigenic properties through its ability to release 
growth hormone (GH) and induce appetite [38]. Currently, ghrelin is the only known orexigenic 
peripheral hormone that is predominantly secreted within the gastric mucosa [39]. About 65% of 
plasma ghrelin is produced by the X/A-like cells within the oxyntic glands of the stomach [40, 
41], while a smaller amount (~30%) comes from the small intestine. Ghrelin not only plays a role 
in the stimulation of GH release from the pituitary, but also demonstrates a multitude of 
biological functions including appetite regulation and food intake; gastrointestinal motility; 
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gastric acid secretion; endocrine and exocrine pancreatic secretions; glucose and lipid 
metabolism; and cardiovascular and immunologic processes [42].  
Ghrelin stimulates both gastric emptying [43] and gastrin release [44]. In addition, 
ghrelin may also promote appetite through the vagus nerve by facilitating the signal between the 
gut-brain axis [45, 46]. Arnold et al. (2006) studied subdiaphragmatic vagal deafferentation 
(SDA) and its effect on ghrelin-induced eating in rats. In this study, intraperitoneal injections of 
ghrelin encouraged eating as strongly in sham-operated control rats as it did with verified 
complete SDA rats. In rats with total subdiaphragmatic vagotomies, ghrelin also stimulated 
eating. This concluded that the acute eating-stimulatory effect of intraperitoneal ghrelin does not 
require vagal afferent signaling [46].  
Two forms of ghrelin are present in the human body: acylated ghrelin and non-acylated 
ghrelin or desacyl ghrelin [47]. Both forms of ghrelin circulate into the bloodstream bound to 
lipoproteins [48]. The majority of circulating ghrelin originates from the stomach. Compared to 
the acylated form, non-acylated ghrelin circulates in larger amounts, but it does not dislocate 
ghrelin from its hypothalamic and pituitary binding sites [47]. Although acylated ghrelin only 
accounts for 10–20% of circulating ghrelin, it is the form believed to be responsible for appetite 
stimulation [38, 49]. The addition of an n-octanoyl group in acylated ghrelin allows it to cross 
the BBB and act on the CNS via a saturable transport system which consequently increases food 
intake [35]. By stimulating the release of GH, acylated ghrelin promotes appetite through its 
action on the brain [35]. It also influences feeding through GHS-R expressed on NPY neurons. 
Both acylated and desacyl ghrelin act on the GHS-R of the NPY/AgRP arcuate neurons, which 
stimulates the up-regulation of NPY and AgRP, ultimately increasing energy intake [50] and 
demonstrating that its effects are antagonistic to anorexigenic hormones [51]. Total ghrelin 
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measures do not provide an accurate representation of changes in the active form of ghrelin. 
Therefore, studying the acylated form of ghrelin is more informative for neuroendocrine energy 
intake regulation when investigating the effects of exercise on appetite stimulation [52]. 
Furthermore, acylated ghrelin appears to be more susceptible to acute manipulation of energy 
balance through energy deficits or macronutrient ingestion [42].  
Levels of ghrelin differ throughout the day. High levels of ghrelin occur both before food 
intake and during the night, along with a reduction of ghrelin immediately following food 
ingestion. This shows that ghrelin may be an essential factor in meal initiation [15, 40, 53-55]. 
Additionally, ghrelin levels can change according to an acute or chronic nutritional status. 
Fasting will cause an elevation of ghrelin levels in which levels decrease immediately following 
food intake with postprandial levels decreased 60–120 minutes after ingestion [12, 40, 53, 55, 
56]. Fasting also leads to an increased expression of ghrelin in the stomach with higher plasma 
concentrations, therefore; ghrelin induces both food intake and adiposity [57]. Ghrelin levels are 
elevated in a fasted state and decrease postprandially in proportion to the caloric load and 
circulating micronutrient signals of a meal, showing that resting ghrelin levels are inversely 
associated with adiposity.[12, 39, 40, 58].  
The amount of ghrelin secreted by the stomach depends greatly on the nutritional state. 
The suppression of postprandial ghrelin is proportional to the ingested calorie load [58]. Callahan 
et al. (2004) observed an inverse correlation between ghrelin levels and calorie content when 
given meals of increasing calorie content, but with identical nutrient composition in humans 
[58]. They found that when the energy content of a meal is higher, the lag period for recovery of 
ghrelin levels is prolonged and ultimately results in lower caloric intake at the following meal 
[58]. The preprandial increase of ghrelin correlates with the hunger scores in healthy humans to 
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initiate meals voluntarily in the absence of food-related cues [59]. Compared to other 
macronutrients, carbohydrates exert a more suppressive effect on ghrelin secretion when 
consuming an isocaloric low-fat vs. low-carbohydrate diet, thus lowering fat content to total 
energy intake maintains a suppressive effect on ghrelin [29]. Along with acute nutritional status, 
ghrelin levels also represent chronic nutritional states [11], in which the hormone is suppressed 
in obese individuals, but increased in lean individuals [15].  
Body weight gain and adiposity are induced by ghrelin [56] through stimulating food 
intake. It prefers fat ingestion, promoting fat storage, reducing energy expenditure and fat 
utilization, and consequently increasing carbohydrate utilization [42, 60, 61]. Weigle et al. 
(2003) found that low-fat diets have an inhibitory effect on ghrelin levels. This study reported a 
low-fat/high-carbohydrate diet resulted in weight loss without an increase in plasma ghrelin 
levels [29]. Similarly, Nedvidkova et al. (2003) revealed that healthy women who consumed a 
high-carbohydrate diet showed a larger drop in ghrelin levels compared to a high-fat diet [62]. 
Although ghrelin levels decreased in both groups, this shows that ghrelin is more responsive to 
carbohydrates than fat [63]. Furthermore, circulating ghrelin concentrations are negatively 
correlated with body mass index (BMI) [57]. Levels of ghrelin increase when obese individuals 
lose weight, and decrease when anorexia nervosa patients gain weight [64]. In addition, 
circulating ghrelin levels are higher in patients with anorexia nervosa and in animals after 
periods of fasting or in states of cachexia [65, 66] This suggests that ghrelin levels change in 
response to dieting for the maintenance of body weight [66, 67]. However, it is still unclear if 
these hormone alterations are the cause or the consequence of obesity.  
Anorexigenic Gut Hormones 
Glucagon-like peptide-1 (GLP-1) 
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GLP-1 is a 30-amino acid peptide derived from the glucagon precursor, proglucagon [68] 
[69]. Proglucagon is produced within the enteroendocrine L cells of the intestines, primarily the 
ileum and colon, which serves as a precursor for the hormones glucagon, oxyntomodulin, GLP-1 
and glucagon-like peptide-2 (GLP-2). GLP-2 is a 33-amino acid peptide that aides in energy 
homeostasis through acute and chronic effects on gut motility and nutrient ingestion and 
absorption [70]. Various stimuli aid in the release of GLP-1 including glucose, fat, proteins, 
amino acids, long-chain fatty acids, short-chain fatty acids, and bile acids [68]. However, the 
major stimulus for GLP-1 and GLP-2 secretion is the ingestion of nutrients, including glucose, 
fatty acids, and dietary fiber [71]. GLP-1 secretion is also regulated by the parasympathetic 
nervous system and circulating hormones such as cholecystokinin, glucose-dependent 
insulinotropic peptide (GIP) and leptin [68]. When nutrients are ingested, the release of GLP-1 
and GLP-2 into circulation occurs in a biphasic manner, including of a quick (within 10–15 
minutes) early phase followed by a prolonged (30–60 minutes) second phase [71].  
Two different mechanisms are responsible for this biphasic pattern. First, the vagus 
nerve, the neurotransmitter gastrin-releasing peptide, and GIP all contribute to the rapid release 
of GLP-1 and GLP-2 into circulation when the L cells response to nutrient stimuli [71]. 
Secondly, the direct stimulation of the L cells by digested nutrients is responsible for the 
prolonged second phase. GLP-1 is secreted in two active forms, GLP-17-37 and GLP-17-36, but its 
half-life is very short (less than 2 minutes) [72], whereas GLP-2 is more stable, with a half-life of 
approximately 5–7 minutes [73]. GLP-17-36 is the active form that is found at the highest 
concentration in the plasma [69]. The enzyme responsible for this rapid degradation of GLP-1 
and GLP-2 is the inhibitor dipeptidyl-peptidase IV (DPP-IV), which produces the inactive 
peptides GLP-19-37 and GLP-2.  
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GLP-1 plays an important role in glucose and energy metabolism including glucose-
stimulated insulin secretion, inhibition of glucagon secretion and gut motility, and the reduction 
of appetite [68]. GLP-1 regulates blood glucose levels through its combined actions on the 
stimulation of glucose-dependent insulin secretion and the inhibition of glucagon secretion, 
gastric emptying, and food intake. By inhibiting glucagon secretion and delaying gastric 
emptying [74], GLP-1 promotes satiety induction although that mechanism is not completely 
understood.  
Once in circulation, GLP-1 acts by binding to the G-protein coupled GLP-1 receptor 
(GLP-1R). GLP-1R is expressed in pancreatic islets where GLP-1 functions as an incretin 
hormone, which allows for enhanced glucose-dependent insulin to be released postprandially 
[75]. GLP-1R is also present in many CNS areas associated with appetite control including the 
ARC and paraventricular nucleus in the hypothalamus and the area postrema in the brainstem 
[76]. GLP-1 receptors are widely distributed in the brain and peripheral organs such as the 
pancreatic islets and the GIT. In the brain, GLP-1 receptors are found in areas where the control 
of food intake and energy balance are implicated. As an incretin hormone, it stimulates glucose-
induced insulin and inhibits glucagon release [64]. 
GLP-1 is released postprandially into circulation in proportion to the calories ingested 
[77]. Plasma GLP-1 levels in humans increase postprandially and reach a peak within one hour 
and then gradually decrease to basal levels [68]. GLP-1 inhibits food intake and promotes satiety 
in normal, obese, and diabetic humans [78]. A study by Adam and Wererterp-Plantenga (2007) 
analyzed levels of GLP-1 in a group of overweight/obese adults and found that preprandial levels 
were similar in overweight/obese adults compared with normal-weight controls. However, the 
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postprandial GLP-1 response in the overweight/obese adults was significantly blunted 30 
minutes after the test meal compared to the control subjects [14]. 
The actual presence of nutrients in the gut lumen are responsible for the GLP-1 response 
[79]. Accordingly, a very rapid GLP-1 response is seen in humans after ileal instillations of 
lipids or carbohydrates in levels corresponding to the physiological malabsorption of these 
nutrients [80]. The meal response depends on the caloric size of the meal [81] and is strongly 
correlated to the gastric emptying rate [82]. In subjects with accelerated gastric emptying, such 
as gastrectomy or gastric bypass operations in obesity individuals, the secretion of GLP-1 may 
be exaggerated [82, 83]. In such patients, this potentially could be the cause of reactive 
hypoglycemia, due to an inappropriate hyperinsulinemia response [84]. 
Further important effects of GLP-1 include the inhibition of gastrointestinal secretion and 
motility [85, 86]. GLP-1 inhibits gastrin-induced acid secretion in humans [87], which 
subsequently revealed that GLP-1 also inhibits meal-induced secretion as well as gastric 
emptying and pancreatic secretion [86]. GLP-1 activates the ‘ileal brake’ by slowing down the 
rate of gastric emptying, which ultimately slows down nutrient absorption and contributes to the 
reduction of postprandial glycemia and enhanced satiety [88]. The hypothalamus-pituitary-
adrenal axis demonstrates that when undigested nutrients reach the lower intestine, it causes an 
inhibition of gastric emptying, small intestinal transit, gastric acid secretion, pancreatic enzyme 
secretion, and bile acid secretion. This phenomenon in the GIT shows the negative feedback 
mechanism called the ileal brake [68].  
Leptin 
Leptin is a peptide hormone encoded by the obese gene and is primarily produced and 
secreted by mature white adipocytes, but it is also released from the GIT and has been shown to 
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inhibit food intake [89]. In smaller amounts, leptin is also produce in other human tissues 
including the stomach, mammary epithelium, placenta, and heart [90]. Leptin plays a role in 
regulating food intake, energy expenditure, and adiposity, as well as the immune and endocrine 
systems [91]. It acts within specific areas of the hypothalamus to help regulate body weight via 
the negative feedback loop [89]. Leptin influences food intake and energy expenditure by 
inhibiting the NPY/AgRP neurons and directly stimulating the POMC/CART neurons of the 
ARC [92]. It also stimulates energy expenditure and inhibits food intake through acting upon the 
hypothalamic leptin receptors.  
The expression of leptin in adipocytes and its plasma concentration are both positively 
correlated with total adiposity [93]. Additionally, plasma leptin concentrations can be acutely 
modulated by a variety of physiological conditions (starvation-refeeding and cold exposure) and 
hormonal factors (insulin, catecholamines, glucocorticoids, thyroid hormones, gonadal steroids). 
Observations show how starvation can decrease plasma insulin and leptin levels. Obesity is also 
strongly associated with both hyperinsulinemia and hyperleptinemia [94, 95].  
Leptin is primarily involved in the long-term regulation of energy balance as it is released 
into circulation by the adipose tissue as a function of the energy stores [29]. Although 
deficiencies of leptin or the leptin receptor results in obesity, most human obesity is associated 
with elevated leptin levels [94, 96].  
Pancreatic Polypeptide (PP) 
Pancreatic polypeptide is part of the PP fold peptide family that is synthesized and 
released from the endocrine pancreas [28]. PP is secreted from pancreatic F cells in response to 
vagal sensing, cholecystokinin and ghrelin concentrations, and sympathetic nervous system 
activation. PP shows a preferential binding to the Y4 and Y5 receptors. It is secreted in 
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proportion to food intake in which plasma levels can be elevated for up to six hours [97]. 
Reducing food intake through gastric emptying and motility by the inhibition of pancreatic 
secretions and gallbladder motility is its major physiological role. Individuals classified as 
morbidly obese or individuals with Prader-Willi syndrome show blunted PP responses 
postprandially [98]. In addition, individuals with Prader-Willi syndrome will decreases food 
intake with an administration of PP. Food ingestion is the main stimulus for PP release, although, 
other factors can alter circulating levels. When creating an energy deficit, exercise can produce 
an increase in PP levels [99]. 
PYY 
Peptide YY is a 36-amino acid peptide belonging to the NPY family and is secreted 
primarily from the L cells within the intestinal mucosa of the ileum and colon in response to 
nutrient intake [100]. After nutrient ingestion, PYY can remain elevated for ~ 120 minutes after 
the meal [101]. PYY targets the Y2 receptor that is highly expressed in NPY neurons. The 
binding of PYY to the Y2 receptor leads to the inhibition of food intake [102]. PYY is also 
associated with energy homeostasis. PYY is part of a family of peptides including NPY and is 
known to alter food intake and prevent weight gain. PYY exists in two forms in human blood; 
PYY1-36 and PYY3-36, the latter of which is the predominant form and preferentially binds to the 
inhibitory presynaptic Y2 receptor subtypes. These receptors are expressed in the appetite 
regulatory center of the ARC within the hypothalamus. This hormone is similar to both NPY and 
PP, demonstrating the binding affinity for Y receptors. PYY3-36  has a potent effect on feeding, 
however; the influence of PYY on regulation of food intake might not be exclusive to the 
hypothalamus [11]. 
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PYY has been reported to be reduced or unaltered with obesity and increased with 
anorexia nervosa [103]. Infusion of PYY3-36  in both lean and obese subjects, reduced food 
consumption, although; there are conflicting results suggesting that PYY infusion may need to be 
administered in a specific infusion pattern to exert its anorexigenic effects [99]. Infusing PYY3-36 
into both lean and obese humans resulted in a 30% reduction in calorie intake [102].  
Alterations in Hunger Hormones 
Diabetes/Obesity 
Obesity, prediabetes, and T2DM are interrelated disorders within a disease continuum 
[104]. Generally, as the number of metabolic abnormalities increase, ghrelin levels decrease 
[105]. In both obese subjects [57] and subjects with T2DM, ghrelin levels are suppressed [15]. 
However, the degree of obesity drives the level of impairment of ghrelin [57]. For example, lean 
type 2 diabetic patients do not have decreased ghrelin levels [15]. Shiiya et al. (2002) studied 
plasma concentrations in patients with obesity, anorexia, and T2DM along with ghrelin 
responses to a glucose load and a test meal in normal and diabetic patients, respectively. The test 
meal given to the diabetic group consisted of a 450-calorie meal with half of the calories coming 
from carbohydrates. Blood was drawn at 0, 30, 60, and 120 minutes postprandially. Mean plasma 
ghrelin concentrations showed no significant difference between normal-weight healthy subjects 
and normal-weight diabetics. This study also showed no statistical difference in plasma ghrelin 
concentrations between diabetic and nondiabetic groups [15]. The meal tolerance test showed 
plasma ghrelin concentrations for diabetics decreased by 60 minutes after eating then increased 
thereafter. 
Fasting ghrelin levels are lower in obese subjects than in normal weight subjects [15, 40, 
57] and are negatively correlated to percent body fat [57]. However, ghrelin levels appear to 
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increase when obese subjects lose weight [67]. Hansen et al. (2002) studied eight obese women 
undergoing a six-month weight loss program. Plasma ghrelin levels were tested pre- and post-
weight loss. With a 5% weight loss, fasting plasma ghrelin concentration was increased by 12% 
following weight loss, showing that the increase in ghrelin was positively correlated with weight 
reduction [67]. Weight loss induced by food restriction and by long-term exercise also increases 
ghrelin levels [106, 107]. Conversely, weight gain that results from overfeeding, pregnancy, 
olanzapine treatment, and a high-fat diet decreases ghrelin levels [12, 42, 108]. 
GLP-1 impairment and postprandial deficiency can also occur in obese individuals.  
However, findings regarding GLP-1 levels in obesity have been inconsistent. Few studies 
reported reduced GLP-1 levels in obese subjects compared to lean subjects [14, 78]. Both 
Muscelli et al. (2008) and Toft-Nielsen et al. (2001) found that postprandial GLP-1 secretion was 
found to be inversely related to BMI [109, 110]. Equally, other studies have not reported any 
differences in GLP-1 between lean and obese individuals [81, 111]. 
Ghrelin and glucose homeostasis 
Plasma glucose and insulin have suppressive effects on ghrelin and are therefore 
important for ghrelin regulation [15, 112]. Tong et al. (2010) demonstrated that circulating 
ghrelin suppressed glucose-stimulated insulin secretion and deteriorated glucose tolerance in 
healthy subjects. The findings of this study raise the possibility that endogenous ghrelin could 
have a role in physiologic insulin secretion in which ghrelin antagonists could improve beta-cell 
function [113]. Compensatory hyperinsulinemia as a result of insulin resistance was associated 
with significantly reduced levels of ghrelin, which showed that fasting plasma concentration of 
total ghrelin was lower among subjects with T2DM compared to those without [13]. 
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Subjects with insulin resistance such as T2DM show lower ghrelin levels. Also, insulin 
has been shown to inhibit ghrelin levels [114, 115]. Lucidi et al. (2002) further studied this 
concept by comparing plasma ghrelin concentrations after a short-term insulin infusion in 
healthy volunteers to either cause hypoglycemia or not (euglycemia). In both trials, plasma 
ghrelin concentrations significantly decreased (p < 0.01) after insulin infusion (hypoglycemia by 
14%, euglycemia by 22%). A strong correlation (r = 0.91, p < 0.002) between insulin sensitivity 
and the percent suppression of ghrelin from baseline was found [114]. These data show that 
ghrelin is not required for the hormonal defenses against insulin-induced hypoglycemia and that 
insulin can suppress ghrelin levels in healthy humans. Moreover, these results demonstrate the 
possibility that postprandial hyperinsulinemia is responsible for the reduction of ghrelin that 
occurs during food intake.  
Many human and animal studies have demonstrated that there is a negative correlation 
between circulating ghrelin levels and insulin secretion [112, 115, 116]. For example, Saad et al. 
(2002) studied eight non-diabetic subjects following a 10-hour overnight fast for infusion of 
insulin and glucose. Human insulin was infused for two hours while a variable infusion of 20% 
glucose was given to maintain plasma glucose at a fasting level. Blood samples were collected 
over the two hours to determine plasma insulin and ghrelin concentrations. Plasma ghrelin 
decreased by 90 minutes and continued to be suppressed for 15 minutes after the insulin infusion 
was discontinued. Consequently, plasma ghrelin levels rapidly increased to near-basal values 
within 60 minutes. The reciprocal relationship between insulin and ghrelin was observed 
consistently with the maximum insulin-induced suppression of ghrelin ranging from 19–64% and 
occurring 90–135 minutes after starting the insulin infusion [115]. The findings from this study 
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indicate that insulin is a physiological and dynamic modulator of plasma ghrelin. Also, 
insulinemia may possibly mediate the effects of nutritional status on its concentration. 
In another study by Purnell et al. (2003), postprandial suppression of ghrelin correlated 
with a rise in insulin [117]. Sixty adult men and women with various ages and weights 
participated in this study. They were characterized in terms of body composition and hormone 
levels. Blood samples were taken over a 24-hour period ever 30 minutes from 8:00 am to 9:00 
pm, then every hour until 8:00 am the next morning. Fasting ghrelin levels correlated positively 
with age and negatively with BMI. Fasting ghrelin levels correlated most strongly with insulin 
levels (p = 0.002). Also, meal induced ghrelin suppression correlated with the postprandial rise 
in insulin (p < 0.05) [117]. These data are consistent with the hypothesis that insulin may 
negatively regulate ghrelin. 
Djurhuus et al. (2002) demonstrated that ghrelin and GLP-1 levels are negatively 
correlated after glucose intake [118]. They studied healthy lean women who came into the 
laboratory after a 10–12 hour fast for an oral glucose tolerance test (OGTT). Following a 30-
minute rest, a basal blood sample was drawn and 75 g of glucose was ingested in a liquid form. 
Every 15 minutes for 300 minutes, blood was drawn to measure plasma glucose, insulin, ghrelin, 
and GLP-1. Plasma GLP-1 levels almost doubled after the OGTT. After the OGTT, circulating 
ghrelin levels were substantially suppressed. This novel observation of an inverse relationship 
between GLP-1 and ghrelin promotes the possibility in which ghrelin influences GLP-1 secretion 
or perhaps GLP-1 influences ghrelin secretion.  
The Incretin Effect 
The incretin effect refers to the augmentation of insulin secretion after an oral 
administration of glucose compared to an intravenous administration of glucose at matched 
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glucose levels. The incretin effect is mainly caused by the gut hormones GIP and GLP-1 and 
their action on the beta-cells of the pancreas. Success in using incretin therapy as a glucose-
lowering strategy in T2DM has provoked a recent interest. In non-diabetic subjects, the incretin 
effect is responsible for 50–70% of insulin release during oral glucose administration while in 
T2DM patients, the incretin effect is impaired and contributes to only 20–35% of the insulin 
response to oral glucose [119]. 
Even though the reports in the literature are mixed, most studies including GIP and GLP-
1 secretory responses to oral glucose or a mixed meal have shown fairly normal results in 
T2DM. In contrast, insulinotropic effects on both GIP and GLP-1 are impaired in diabetic 
individuals. A greater suppression of insulin secretion augmentation occurs with GIP compared 
to GLP-1 [119]. The cause of these defects suggests either a defective beta-cell receptor 
expression or a post-receptor defect. The defects are secondary to the diabetic environment or 
defective beta-cell function in general which results in a defective incretin effect and genetic 
factors that initiate incretin hormone resistance [120]. Identifying theses mechanisms in greater 
detail are important for understanding the strengths, weaknesses, and efficacy of incretin therapy 
in individuals to specifically target this glucose-lowering therapy. 
Sex Differences 
A few studies have investigated sex differences in appetite response to nutrient 
manipulations finding that women are more sensitive to overfeeding [121] and macronutrient 
changes [122]. This leads to greater changes in appetite sensation ratings and/or subsequent 
energy intake in women. However, it is difficult to generalize these results since almost all 
previous studies examined the acute effect of a single nutrient/food on appetite sensations. A 
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given nutrient or food may act differently on appetite sensations depending on interaction with 
other nutrients and foods present in the diet. 
Hagobian et al. (2013) recently found that men and women do not differ in their 
hormonal or appetite responses to an exercise bout matched for relative energy expenditure 
(~30% of estimated daily energy expenditure). Both sexes had significant reductions in relative 
energy intake post-exercise and no noticeable changes in acylated ghrelin levels [123]. 
Regardless, it is generally accepted that women increase their energy intake during the luteal 
phase compared to the follicular phase of their menstrual cycle [124, 125]. For example, 
Campolier et al. (2016) investigated whether appetite responses vary after consuming the same 
meal in the different phases of the menstrual cycle. Results showed significant differences in 
ovarian and satiety hormone levels across the phases of the menstrual cycle [126]. Therefore, 
nutrition-related studies often avoid the participation of pre-menopausal women due to the 
potential effects of the menstrual cycle on appetite regulation.  
Acute Exercise on Appetite Regulation  
Understanding the impact of exercise on hormones involved in appetite regulation may 
provide insight to the mechanisms of energy balance regulation. Previously shown, exercise can 
increase satiety and suppress hunger [23, 24, 127-129]. At rest, acylated ghrelin is known to 
promote food intake while satiety hormones such as PYY, PP, and GLP-1 are known to inhibit 
food intake. Exercise has been shown to have various effects on these hormones in addition to 
the factors of exercise intensity, duration, and mode. Acute exercise appears to be intensity-
dependent with increasing intensities resulting in a greater suppression of orexigenic signals and 
a greater stimulation of anorexigenic signals [130].  
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The effect of exercise mode is of particular interest because variety in exercise training is 
a potential factor in compliance. The effect of exercise on these hormones and energy intake has 
been studied extensively, although; no definitive consensus is present. There is evidence 
indicating that the concentration of acylated ghrelin is suppressed after vigorous endurance 
exercise while concentrations of the anorexigenic hormones (PYY, PP, and GLP-1) are increased 
[23, 24]. For example, Broom et al. (2009) examined resistance and aerobic exercises in 11 
healthy males with a randomized crossover design. Each subject underwent three trials: 90-
minute free weight lifting session (resistance training); 60-minute run (aerobic exercise); and 
control (rest). The results revealed a significance suppression of acylated ghrelin during both 
aerobic and resistance exercise along with an increased concentration of PYY during aerobic 
exercise [24] compared to the control trial.  
Ghrelin 
Burns et al. (2007) reported that the suppression of appetite during severe exercise was 
not related to the suppression of total ghrelin [127]. Total plasma ghrelin changes do not seem 
likely to occur, although, reductions of 9–54% have been observed in a few studies compared to 
pre-exercise or a sedentary control where exercise intensity did not seem to have an influence 
[127, 131-133]. On the other hand, acylated ghrelin is more relevant to moderate-intensity 
aerobic exercise (< 75% VO2max, 30–90 minutes) and has demonstrated 14–60% reductions in 
concentration compared to pre-exercise or sedentary controls [24, 128, 132].  
Although, there is some evidence that shows exercises at higher intensities suppress 
hunger, long duration exercise can also suppress acylated ghrelin and appetite [23, 24]. Previous 
studies have demonstrated appetite suppression during and briefly after intense bout of exercise 
(> 60% of VO2max) [23, 134]. Most studies have the bouts of exercise conducted at intensities of 
23 
 
< 75% VO2max. Deighton et al. (2013) shows evidence that supramaximal exercise may be more 
potent for suppressing acylated than vigorous endurance exercise (~ 68% VO2max) [132]. 
However, the supramaximal sprint exercise led to higher hunger levels later on in the 
observation, albeit no changes in energy intake [132]. It has been suggested that studies 
involving exercises that produce a greater metabolic and mechanical demand, are more likely to 
suppress levels of hunger and acylated ghrelin [23, 128]. In one study, 12 weeks of training led 
to a greater change and suppression of acylated ghrelin postprandially while levels of GLP-1 
tended towards greater increases (1.5–2 hours) postprandially [135].  
Interestingly, exercise-induced satiety appears in the presence of decreased circulating 
levels of ghrelin independent of changes in body weight [23, 24, 128]. The effects of an acute 
bout of brisk walking on appetite, energy intake, and plasma acylated ghrelin were measured by 
King 2010a [136]. Fourteen young males completed two 8-hour trials (one brisk walking for 60 
minutes and one control). During the main trials, ad libitum buffet meals were offered in which 
appetite was assessed at 30-minute intervals throughout. Results show that the acute bout of 
exercise did not significantly influence appetite, energy intake, or acylated ghrelin during or after 
exercise [136]. Although, participants did not compensate for the energy expended during 
exercise showing an energy deficit occurred. 
Broom et al. (2007) studied nine male subjects who participated in two, 9-hour trials 
(exercise + rest). The exercise trial consisted of a 60-minute run at 72% VO2max, rested for eight 
hours followed by a test meal. AUC values for plasma acylated ghrelin concentrations were 
lower over the first three hours compared to the control trial [23]. Using the visual analog scale 
(VAS), values for hunger were lower over the first three hours of the exercise trial compared to 
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the control trial. The results from this study demonstrate how plasma acylated ghrelin and hunger 
levels are both suppressed during and following a high-intensity exercise. 
Adiposity alters acylated ghrelin levels, but adiposity can potentially alter the effect of 
exercise and feeding on acylated ghrelin responses. Heden et al. (2013) wanted to determine 
whether adiposity influences the effect of exercise and feeding on acylated ghrelin, hunger, and 
fullness. Fourteen normal weight and 14 obese individuals completed two trials including 
exercise (1-hour of treadmill walking at 55–60% peak O2 uptake) and no exercise trial. Blood 
samples were taken to assess ghrelin while VAS questionnaires were used to assess perceived 
hunger and fullness. Exercise reduced fasting acylated ghrelin concentrations by 18% in the 
normal weight individuals [137]. Also, in response to feeding, the change in acylated ghrelin was 
attenuated by 39%. However, perceived hunger and fullness were not altered. In obese 
individuals, there were no changes in fasting or postprandial acylated ghrelin concentrations with 
the exercise trial. Also, postprandial fullness was attenuated by 46% compared to the no exercise 
trial. They concluded that exercise preformed the night before a meal suppresses acylated ghrelin 
in normal weight individuals despite unaltered perceived hunger or fullness. Although obese 
individuals saw no change in acylated ghrelin levels, the exercise trial reduced the fullness 
response to the test meal [137].  
GLP-1 
Moderate-intensity aerobic exercise (50–70% VO2max, 30–60 minutes) increases active 
GLP-1 concentrations by 11–50% [26, 27] and total GLP-1 by 16–1477% [129, 138] compared 
to non-exercise controls. For example, Ueda et al. (2009b) examined whether gut hormone levels 
differ between obese males and normal weight subjects. They found that 60 minutes of cycling at 
50% VO2max (moderate-intensity) resulted in a significant increase in GLP-1 concentrations after 
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exercise in both obese subjects and normal weight subjects compared to the rest condition [27]. 
Only a few studies have examined the effects of high exercise intensity on GLP-1 with 
ambiguous results. Beaulieu et al. (2015) demonstrated that sprint interval training resulted in no 
change in active GLP-1[139]. Alternatively, Chanoine et al. (2008) investigated the effects of 
exercise on GLP-1 concentrations and appetite markers. Normal weight and at risk of overweight 
male individuals participated in this study. Five consecutive days of 1-hour aerobic exercises 
were completed. The exercise seemed to cause an increase in the acute GLP-1 response to the 
test meal, which was similar in both groups. Although, there was no significant correlation 
between markers of GLP-1 concentrations and appetite [140].  
Diabetes 
The functional relevance of the disruption of ghrelin levels in obesity and T2DM is not 
clear [10]. Several reports have found that insulin and glucose had no direct effect on acylated 
ghrelin concentrations [23, 128, 141], nor did insulin sensitivity have any relationship with 
acylated ghrelin [142]. However, King et al. (2015) measured hormone levels the day after 
prolonged exercise, which may lead to conflicting results. Importantly, the elevations of plasma 
glucose following a high-intensity exercise bout may contribute to increased levels of GLP-1 
given its established role as an incretin hormone, which could stimulate insulin secretion in 
response to plasma glucose [120].  
Acute effects of fast walking have shown opposing results [25]. Deguchi et al. (2016) 
used fast walking as the intervention for subjects with T2DM. They believed it was important for 
patients to independently determine the appropriate amount of exercise to obtain maximum 
benefit with the lowest risk in their daily life. Walking was the intervention with comparisons 
between natural walking and fast walking. Because T2DM patients are typically sedentary in 
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their daily life, exercise intensity was set at a relatively low level [143]. A randomized crossover 
clinical trial was used to determine the immediate effects of walking on postprandial blood 
glucose in patients with T2DM. Fourteen participants were randomly allocated to three walking 
programs (natural walking, 10% fast walking, 20% fast walking) without changing diet or 
medications. Each walking program consisted of treadmill walking for 30 minutes, one hour 
after lunch. Fast walking speeds were calculated from the subjects’ self-selected walking speed 
at the screening visit. The primary outcome showed fast walking reduced postprandial blood 
glucose levels in an intensity-dependent manner. During 15 and 30 minutes of 10% and 20% fast 
walking, postprandial blood glucose levels decreased acutely. However, the difference was not 
significant, showing that patients with T2DM may also experience the same immediate effects 
on postprandial blood glucose levels as a results of 20% fast walking for 30 minutes as they can 
with 10% fast walking for 30 minutes [25]. As a result of this study, T2DM patients could easily 
use this method of walking to determine their exercise intensity, making it possible to adapt to an 
exercise program in their daily life. 
Knudsen et al. (2013) compared exercise-induced postprandial satiety and ghrelin 
responses in overweight subjects with T2DM compared to healthy controls. Baseline levels of 
total and acylated ghrelin were significantly lower in subjects with T2DM compared to healthy 
subjects [10]. Because fasting levels of ghrelin were lower in the overweight T2DM group 
compared to the overweight healthy controls, this suggests that the diabetic state could be a 
contributing factor in the impairment of ghrelin levels. Although plasma ghrelin levels were 
unaffected by exercise, there was an increase in postprandial fullness in the T2DM group. These 
data suggest that the presence of T2DM suppresses ghrelin levels and drives poor appetite 
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regulation. However, a single bout of exercise is sufficient enough to restore the oral glucose-
induced fullness independently of ghrelin [10]. 
A study conducted by Hordern et al. (2011) demonstrated the effects of short-term 
exercise training in patients with T2DM. Exercise training included a four-week regimen of two 
1-hour sessions and one 30-minute session per week for four weeks. Over the exercise training 
period, there were significant decreases in resting heart rate, systolic blood pressure, and fat mass 
[144]. There was a significant time effect in the blood glucose decrease pre- to post exercise 
session during the exercise sessions over the four-week period. Also, there was a significant (p < 
0.05) difference between the percent decrease observed in week one compared to week four 
[144]. The main finding of this study shows that the acute blood glucose lowering effect of a 
single bout of exercise is augmented over a four-week period in patients with T2DM.  
Perceived Hunger 
A VAS is a measurement instrument that helps to measure a characteristic or attitude that 
is believed to range across a continuous line of values that cannot be directly measured easily 
[145]. A horizontal line, 100 mm in length is anchored with word descriptions at either end in 
which the subject would mark a line at the point where they feel best represents the perception of 
their current state. The score is determined by measuring in millimeters from the left hand end of 
the line to the point that the subject marks [145].  
A VAS has been used to assess subjective ratings of hunger, satisfaction, fullness, and 
prospective food consumption [146]. Subjects were asked: how hungry do you feel, how 
satisfied do you feel, how full do you feel, and how much do you think you can eat. Hunger 
assessment at one end (0 mm) of the scale had the descriptor “not at all hungry” and the other 
extreme (100 mm) was the descriptor “totally hungry”. Hagobian et al. (2013) utilized this 
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perceived hunger scale and showed no significant difference was seen between sexes in any 
appetite rating (hunger, fullness, satisfaction) when using the VAS [123].   
Vatansever-Ozen et al. (2011) demonstrated the relationship between perceived hunger 
(VAS) and biological hunger (acylated ghrelin) with the variable of exercise. Over 240 minutes, 
the exercise group had a significantly higher perceived hunger rating at 120 and 180 minutes (p < 
0.05) compared to the rest (control) group. Baseline fasting plasma acylated ghrelin 
concentrations did not differ significantly between trials. However, plasma acylated ghrelin was 
significantly lower (p < 0.05) at 120 and 240 minutes in the exercise group compared to the rest 
group [133].  
Prado et al. (2014) performed a study with obese girls investigating the effects of exercise 
at ventilatory threshold on hunger scores. The control group (rest) at 150 minutes had 
significantly higher hunger scores compared to the exercise group. The magnitude of change in 
percentage increase in hunger scores in the control condition was almost 100% and 275% from 
baseline to 30 minutes and 150 minutes, respectively. Interestingly, the magnitude of change for 
increased hunger scores in the exercise condition was only 13% from baseline to 30 minutes 
(nonsignificant; p > 0.05), but it increased by 139% from baseline to 150 minutes (p = 0.01) 
[147].  
Alternative Therapies 
Infusion of Satiety Hormones 
One therapy studied for the treatment of obesity includes intravenous infusion of satiety 
hormones to replicate the physiology of the fed state in humans. Infusion of GLP-17-36 in humans 
showed a great increase in insulin secretion, glucagon suppression, and lower glucose levels 
prompting the consideration of using the hormone as a pharmacological incretin in the 
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management of T2DM [75]. Short-term administration of PYY3–36 and GLP-1 separately leads to 
a reduction in energy intake by mechanisms involving changes in central regulation of appetite 
[76]. Flint et al. (1998) examined the effect of GLP-1 infusion in young healthy men. Infusion of 
GLP-1 mixed with saline (treatment) or saline alone (control) was infused at the start of the test 
meal for breakfast. Blood samples were obtained along with the completion of VAS scores. The 
GLP-1 infusion satiety and fullness compared with the placebo. Also, spontaneous energy intake 
at the ad libitum meal, was reduced significantly by 12% in the treatment group compared to the 
control group [148].  
Schmidt et al. (2014) conducted a study to test the outcomes of PYY3–36 and GLP-1 
administration alone and in combination. Compared with the saline placebo, PYY3–36 and GLP-1 
alone had no effect on energy intake, however; the combination of both hormones resulted in a 
significant reduction in ad libitum energy intake [17]. Although, increased subjective ratings of 
nausea was present with the infusion. 
Gastric Sleeve  
Another treatment for obesity and diabetes management is the possible role of the sleeve 
gastrectomy. Insulin secretion and peripheral insulin sensitivity were studied by Basso et al. 
(2011) utilizing the intravenous glucose tolerance test. Obese type 2 diabetics and nondiabetic 
obese patients were evaluated prior to and after their sleeve gastrectomy. The first phase of 
insulin secretion promptly improved following surgery for the diabetic patients. The second 
phase of insulin secretion significantly decreased for all groups following the sleeve gastrectomy 
showing an improvement in insulin peripheral sensitivity. Intravenous glucose stimulation 
determined a decrease in ghrelin levels and an increase in GLP-1 and PYY values for both pre- 
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and postoperative groups. Basal and intravenous stimulated GLP-1 and PYY postoperative 
values were higher than preoperative values in all groups [18].  
Due to ghrelin being produced primarily in the stomach, weight loss after gastric bypass 
surgery may be accompanied by impaired ghrelin secretion. Cummings et al. (2002) studied 
hormone levels in obese subjects before and after a dietary weight loss program and compared it 
to obese individuals who had undergone gastric bypass surgery with normal weight controls [12]. 
They found that weight loss induced by gastric bypass surgery produce contradictory results in 
ghrelin levels: an increase [149, 150], a decrease [12, 151] or no change at all [152].  
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CHAPTER 3: 
METHODOLOGY 
Subjects 
Subjects were recruited from the community of Las Vegas through fliers, e-mails, word-
of-mouth, and online announcements (Appendix A). All subjects were healthy men and women 
between the ages of 45–69 years, BMI 25–40 kg/m2, nonsmoking, and inactive (fewer than two 
20-minute bouts of exercise per week during the previous three months). Volunteers were asked 
to complete an online survey addressing the inclusion criteria to screen for initial eligibility. 
Individuals completed a physical activity readiness questionnaire (Par-Q) to determine if they 
were healthy enough to exercise (Appendix B). Anyone who answered “yes” to any of the 
questions on the Par-Q was excluded for safety reasons. All subjects were free of unsolved 
medical conditions, not diagnosed with a chronic disease including diabetes, and weight stable 
within the past three months (+/- 3 kg). If female, they no longer had a menstrual cycle. In 
addition, all subjects were willing to follow the study protocol and were able to walk on a 
treadmill at a moderate pace of ~ 2.5 miles per hour (mph).   
An a priori power analysis was performed to determine the sample size necessary to 
detect significant changes in the hunger hormones acylated ghrelin and GLP-1. From previous 
available data [27, 128], it was determined that for a within-subjects repeated measures design, 
to detect significance at a 0.05% significance level and power > 0.80 with an expected 20% 
dropout rate, 4–5 subjects would need to be recruited. For changes in postprandial GLP-1 after a 
single acute bout of exercise, one previous study achieved statistical power for detecting 
differences in two-hour AUC with 14 subjects [27]. Another study demonstrated a significant 
change in acylated ghrelin over a 90-minute exercise period with nine subjects [128]. The 
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University of Nevada, Las Vegas Institutional Review Board (IRB) approved this study and all 
volunteers provided written informed consent prior to participation (see Appendix C for IRB 
approval and informed consent). 
Experimental Design 
 A randomized crossover design with two different test days, one control (rest) and one 
treatment (exercise) was used in this study. All trials were separated by approximately one week. 
Subjects received compensation on a graded scale for each of the study visits.  
 
Figure 1. Study design from recruitment to trial implementation. Subjects completed two trials in 
a randomized order spaced one week apart. 
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Screening Visit 
Participants who met the inclusion criteria obtained from the online survey were 
scheduled to attend an initial screening visit. All subjects were given a written consent form to 
fill out and sign. Potential subjects were included if their fasting capillary blood sugar (obtained 
by fingerstick) was within the prediabetic range (100–125 mg/dL). Individuals who meet all 
preliminary inclusion criteria were then further assessed. 
Subjects completed a medical history questionnaire to verify the absence of any 
contraindications to the exercise and dietary protocols. Height was measured on a stadiometer 
and recorded in centimeters. Weight and body composition were measured using a scale with 
bioelectrical impedance analysis (InBodyTM 770, Seoul, South Korea). Waist circumference was 
measured per the American College of Sports Medicine guidelines and recorded in centimeters 
[153]. 
During this visit, the preferred walking speed of each subject was obtained by using a 
validated 10-meter walk test [154]. Briefly, each subject walked at a comfortable, typical 
walking pace across a 10-meter measured area four different times. The first time was not 
recorded, as it was a practice trial. For the following three trials, only the middle six-meters were 
measured to eliminate the acceleration and deceleration effects. Start and stop time was recorded 
when the toes of the leading foot crossed the two-meter and the eight-meter mark, respectively. 
The time taken to complete each of the last three walks was measured and used to calculate 
preferred walking speed in mph. 
Diet 
 Standardized meals were used for a 24-hour period the day prior to each of the two 
testing days. Meals were prepared in the kitchen housed in the College of Hotel Administration 
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at the University of Nevada, Las Vegas by registered dietitians and trained nutrition students. 
Meals were frozen and given to subjects prior to each testing visit. Two days before each visit, 
subjects arrived at the laboratory to pick up their meals. On the day prior to each experimental 
day, the subjects consumed the standardized meal plan starting with breakfast. No food was 
consumed after the standardized dinner meal and participants fasted overnight with the exception 
of water consumption until they arrived in the research laboratory the following morning. Meal 
composition was specifically designed to mirror a typical American diet [155]. Carbohydrates 
made up 50% of the total calories with protein at 15%, and fat at 35%. The total calories were ~ 
2000 for each day. 
At each visit, subjects consumed identical test meals comprised of a common breakfast 
meal including a bagel with butter (20 g), apple juice (8 oz.) and added sugar (6 tsp.). The meal 
was a total of 670 calories with the macronutrient composition of 70% carbohydrate, 23% fat, 
and 7% protein.  
Study Trials 
Two additional visits (~ 2 hours each) were scheduled after the baseline visit. Each visit 
occurred approximately one week apart and subjects were asked to arrive at the laboratory at the 
same time of day for each visit. The order of the two conditions was randomly determined for 
each individual. Subjects began testing between 6:00 am and 7:00 am following at least a 10-
hour overnight fast. Subjects were instructed to remain sedentary the previous day and the 
morning of testing.  
Fasting venous blood samples were collected by a trained phlebotomist. All blood draws 
were processed and frozen in the lab until analysis. After the fasting blood draw, subjects were 
given ten minutes to consume the test meal (bagel + juice). The two-hour clock started following 
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the first bite of the meal. Acylated ghrelin and GLP-1 blood samples were collected at minutes 0, 
60, and 120. A VAS (Appendix B) was used to measure subjective hunger and satiety levels at 0, 
60, and 120 minutes. Subjects were not allowed to consume any food or beverage (with the 
exception of water and the test meal) during the visit. A snack (High Protein Ensure) was 
provided when testing was over.  
1. CON: After consuming the test meal, subjects remained in the lab for blood testing 
with minimal activity for the remainder of the two hours.  
2. WALK: After consuming the test meal, subjects were given five minutes to transition 
to the treadmill in the exercise physiology lab. At minute 15, subjects began walking 
on a motorized treadmill at their calculated preferred walking speed (mean = 2.49 ± 
0.31 mph). Heart rate was continuously monitored during exercise using a heart rate 
monitor (Polar Electro Oy, Kempele, Finland). Venous blood samples were measured 
immediately following the walk at minute 30. Subjects then rested for the remaining 
1.5 hours and further blood samples were taken.  
Blood Collection 
A fasting venous blood sample was collected by a trained phlebotomist to assess for 
active GLP-1 and acylated ghrelin. Post-meal blood samples were collected for two hours by the 
trained phlebotomist. This included a total of three blood samples taken (0, 60, and 120 minutes) 
to be assayed using ELISA (Enzyme-linked immunosorbent assay) kits. The concentrations of 
acylated ghrelin and active GLP-1 were determined using Human Ghrelin Active ELISA kit 
(EMD Millipore, Billerica, MA, USA) and High Sensitivity GLP-1 Active Chemiluminescent 
ELISA kit (EMD Millipore, Billerica, MA, USA) following the manufacturer’s instructions. The 
sensitivity of the assays was 8 pg/mL (20 µL sample size) for acylated ghrelin and 0.14 pM (20 
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µL sample size) for GLP-1. All samples were assayed in duplicate and samples from one 
participant session were analyzed in the same assay to minimize the effects of inter-assay 
variation. 
Before assays were run, all blood samples were collected directly into EDTA 
(ethylenediaminetetraacetic acid) tubes. Immediately after collection (within 30 seconds), DPP-
IV inhibitor was added to the GLP-1 tubes (10 µL/mL blood) then inverted to mix. For acylated 
ghrelin, blood was collected in EDTA tubes and pefabloc inhibitor was immediately added to the 
blood sample (10 µL/mL blood). All samples were then centrifuged at 3000 repetitions per 
minute (rpm) for 15 minutes at 4°C, using a temperature-controlled centrifuge. Hydrochloric acid 
(HCl) was then added for acylated ghrelin to acidify samples. The acylated ghrelin samples went 
back into the refrigerated centrifuge to be spun for 15 minutes at 3000 rpm. The plasma was then 
aliquoted into Eppendorf tubes and then stored at -20°C for acylated ghrelin and -70°C for GLP-
1 until assayed.  
Biochemical Analysis 
Ghrelin 
For the Human Ghrelin Active ELISA assay procedure, samples were thawed and 10X 
concentrated wash buffer was used to dilute the samples 10-fold by mixing both buffers with 900 
mL de-ionized water. Strips from the microtiter assay plate were assembled in the empty plate 
holder then each well was filled with 300 µL diluted wash buffer. The wash buffer was decanted 
and residual was removed by inverting the plate and tapping it onto absorbent towels. The assay 
plate was washed using this procedure two additional times. Twenty µL matrix solution was then 
added to the blank, standards, and quality control wells. Thirty µL and 10 µL assay buffer was 
added to each of the blank sample wells and the standard/quality control wells, respectively. 
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Duplicate 20 µL ghrelin standards were added in the order of ascending concentrations to the 
appropriate wells. Then, 20 µL quality control one and 20 µL quality control two were added to 
the appropriate wells. In the remaining wells, 20 µL of the samples were added in duplicate. 
Next, 50 µL of the antibody solution mixture was added to each well. The plate was then 
covered and incubated at room temperature for two hours on an orbital microtiter plate shaker at 
500 rpm. After, solutions from the plate were decanted, making sure all residual solutions were 
removed. Wells were washed three times with diluted wash buffer (300 µL per well per wash). 
Then, 100 µL enzyme solution was added to each well before incubation for 30 minute (at room 
temperature on the microtiter plate shaker). Afterwards, wells were washed six times with 
diluted wash buffer and tapped after each wash ensuring all residual buffer was removed. The 
substrate solution (100 µL) was added to each well then incubated on the plate shaker for 20 
minutes. A blue color developed in the ghrelin standard wells with intensity proportional to 
increasing concentrations of ghrelin. After the sealer was removed, 100 µL of stop solution was 
added to each well and the plate was tapped by hand to complete the mixing of solution. Within 
five minutes, absorbance was read at 450 nm and 590 nm in a plate reader.  
GLP-1  
For the high sensitivity GLP-1 active ELISA assay, all reagents and samples were thawed 
to room temperature and 300 µL of diluted wash buffer was added to each well of the plate. 
Wash buffer was decanted to remove residual volume by inverting the plate and tapping it onto 
absorbent towels then repeated two additional times. Next, 50 µL of matrix solution was added to 
blank, standards, and quality control wells. Then, 50 µL assay buffer was added to each of the 
blank and sample wells, 50 µL of standards, and 50 µL of samples were added to the appropriate 
wells. GLP-1 capture antibody (20 µL) was then added to each well. The plate was covered and 
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incubated at room temperature for two hours on an orbital microtiter plate shaker set to 500 rpm. 
Reagents were decanted from the plate and tapped to remove any residual volume. Wells were 
washed three times with 300 µL per well per wash. Detection antibody (100 µL) was added to 
each well before re-covering plate and incubating for one hour at room temperature on the plate 
shaker. The plate was removed, decanted, and washed three times with the wash buffer. Then 
100 µL enzyme solution was added to each well, covered, and incubated with moderate shaking 
at room temperature for 30 minutes. Reagents from the plate were decanted and wells were 
washed six times. Lastly, 100 µL of working substrate solution was added to each well and 
placed on plate shaker for one minute. The assay plate was read by a luminometer plate reader 
within five minutes after adding the substrate and measured at 425 nm. 
Statistics  
All analyses were conducted using the Statistical Package for Social Sciences (SPSS 
Version 24.0, Armonk, NY, USA). Data were reported as mean ± standard deviation (SD) unless 
otherwise noted. All outcome variables were tested for normality using the Shapiro-Wilk test, 
homogeneity using Levine’s test, and sphericity using Mauchly’s test of sphericity, and 
transformed when necessary. Descriptive statistics were used to describe subject characteristics. 
Two-way repeated measures ANOVA (analysis of variance) were used to determine the 
interactive and main effects between the two conditions (exercise + rest). Significance was 
accepted at p < 0.05. 
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CHAPTER 4:  
RESULTS 
Subject Characteristics 
Seventy-eight volunteers completed the initial online eligibility survey. Of these 
individuals, 34 qualified and came into the laboratory for the screening visit. Eighteen 
individuals were excluded at the screening visit due to normal fasting blood glucose 
concentrations, as measured by capillary blood (< 100 mg/dL). One subject declined to 
participate due to denied consent while another declined due to scheduling conflicts. Two 
subjects dropped out after completing their first trial: one for digestive issues and the other for an 
unknown reason. Consequently, 10 subjects (3 males, 7 females) were enrolled and completed all 
trials of this study. 
 
Table 1. Physical characteristics of subjects at baseline. 
 All Subjects (N = 10) Male (N = 3) Female (N = 7) 
Age (yrs) 59.7 ± 6.8 62.0 ± 7.2 58.7 ± 6.9 
Height (cm) 169.9 ± 7.0 173.3 ± 9.2 168.4 ± 6.0 
Weight (kg)  87.9 ± 19.9 89.3 ± 24.0 87.3 ± 20.0 
BMI (kg/m2)  30.7 ± 4.7 29.7 ± 4.6 31.1 ± 5.0 
Waist (cm) 100.6 ± 23.3 88.7 ± 40.5 105.7 ± 12.9 
Body Fat (%) 39.4 ± 7.1 31.2 ± 4.2 42.8 ± 4.7 
Lean Body Mass (kg) 53.2 ± 11.4 61.5 ± 12.9 49.5 ± 9.3 
Glucose (mg/dL) 108.5 ± 6.5 104.3 ± 4.2 110.3 ± 6.7 
Walk Speed (mph)* 
Average HR (bpm) 
2.5 ± 0.3 
97 ± 13.6 
2.2 ± 0.3 
83 ± 13.7 
2.6 ± 0.3 
104 ± 8.2 
 
Values represent mean ± SD. 
*Calculated using the 10-meter walk test. Average of three trials to determine preferred walking 
speed of each subject.  
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Postprandial Ghrelin and GLP-1 
 There were no statistical differences in acylated ghrelin (F = 1.535, p = 0.247) or GLP-1 
(F = 0.003, p = 0.9559) concentration between CON and WALK conditions at any time period 
(Table 2). Figure 2 shows the pattern of ghrelin concentrations over the two-hour postprandial 
period. There were no statistical differences in ghrelin concentrations (range: 419.73–512.44 
pg/mL; p = 0.204) at baseline. There was a main effect of time for ghrelin (F = 41.339; p < 
0.001). Post hoc analysis indicated a significant difference between baseline and 60 minutes (p < 
0.001) and between baseline and 120 minutes (p < 0.001) for acylated ghrelin concentrations. No 
difference was found between 60 minutes and 120 minutes (p = 0.834).  
 
Table 2. Postprandial acylated ghrelin and GLP-1 concentrations and AUC for each condition.  
Values represent mean ± SD. 
P values calculated using paired t-tests for each time point and AUC (p < 0.05). 
 Control Walk P value 
Acylated Ghrelin    
Minute 0 419.73 ± 168.95 512.44 ± 275.03 0.204 
Minute 60  221.19 ± 135.29 295.65 ± 202.89 0.239 
Minute 120  238.86 ± 145.38 269.75 ± 172.41 0.533 
AUC 550.48 ± 272.94 686.75 ± 415.52 0.240 
    
GLP-1    
Minute 0 2.67 ± 2.90 2.13 ± 1.67 0.616 
Minute 60  5.37 ± 2.47 6.20 ± 3.89 0.465 
Minute 120  6.14 ± 3.31 5.13 ± 2.40 0.409 
AUC 10.01 ± 2.97 10.14 ± 5.24 0.918 
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Figure 2. Change in postprandial acylated ghrelin concentrations at baseline and after meal 
consumption. Error bars represent ± standard error of the mean (SEM). CON = control, WALK = 
walking. 
 
 
Figure 3 shows the pattern of GLP-1 concentrations over the two-hour postprandial 
period. There were no statistical differences in ghrelin concentrations at baseline (range: 2.67–
2.13 pM; p = 0.616). There was a main effect of time for GLP-1 (F = 17.968; p < 0.001). Post 
hoc analysis indicated a significant difference between baseline and 60 minutes (p = 0.001) and 
between baseline and 120 minutes (p = 0.002) for GLP-1 concentrations. No difference was 
found between 60 minutes and 120 minutes (p = 0.665). 
The AUC for both acylated ghrelin and GLP-1 are shown in Figure 3. There was no 
significant difference in the AUC for acylated ghrelin between the CON and WALK conditions 
(t = -1.257; p = 0.240). Furthermore, there was no significant difference in the AUC for GLP-1 
between the control and walk conditions (t = -0.107; p = 0.918). 
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Figure 3. Change in postprandial GLP-1 concentrations at baseline and after meal consumption. 
Error bars represent ± SEM. CON = control, WALK = walking. 
 
 
 
 
Figure 4. Comparison of area under the curve for acylated ghrelin and GLP-1 between trials. 
Graph A (p = 0.240; repeated measures ANOVA). Graph B (p = 0.918; repeated measures 
ANOVA). Error bars represent ± SEM. CON = control, WALK = walking. 
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Hunger Hormones and VAS 
Correlations between perceived hunger and biological hunger were weak and 
nonsignificant (p > 0.05) between any measure. No significant correlations were found between 
VAS question one and control (p = 0.260, r = 0.212) or walk (p = 0.401; r = 0.162) for acylated 
ghrelin. No significant correlations were found between VAS question two and control (p = 
0.712; r = 0.072) or walk (p = 0.844; r = -0.038) for GLP-1. No significant correlations were 
found between VAS question three and control (p = 0.339; r = -0.184) or walk (p = 0.872; r = -
0.031) for GLP-1. 
 
Table 3. Perceived hunger scores for each condition. 
Values represent mean ± SD. 
P values calculated using paired t-tests for each time point (p < 0.05). 
The VAS questionnaire was used to quantify perceived hunger ratings. See Appendix B for VAS 
questionnaire. 
 
 
 
There were no statistical differences in VAS question one (F = 0.493, p = 0.5), VAS 
question two (F = 0.037, p = 0.852) or VAS question three (F = 0.562, p = 0.473) between CON 
 Control Walk P value 
Question 1    
Minute 0 4.3 ± 2.6 5.9 ± 1.4 0.119 
Minute 60  2.3 ± 2.2 2.2 ± 1.5 0.833 
Minute 120  3.2 ± 2.5 2.8 ± 2.1 0.487 
    
Question 2    
Minute 0 3.2 ± 1.5 4.4 ± 1.9 0.200 
Minute 60  2.5 ± 2.0 2.4 ± 1.7 0.878 
Minute 120  3.7 ± 2.1 2.9 ± 1.7 0.275 
    
Question 3    
Minute 0 6.1 ± 2.3  4.8 ± 2.4 0.363 
Minute 60  2.8 ± 2.0 3.0 ± 2.2 0.803 
Minute 120  3.8 ± 2.5 3.3 ± 2.1 0.458 
44 
 
and WALK conditions at any time period (Table 3). There was a main effect of time for VAS 
question one (F = 9.292; p = 0.007). Post hoc analysis indicated a significant difference between 
baseline and 60 minutes (p = 0.005) and between baseline and 120 minutes (p = 0.036) for VAS 
question one. No difference was found between 60 minutes and 120 minutes (p = 0.051).  There 
was a main effect of time for VAS question two (F = 4.871; p = 0.02). Post hoc analysis 
indicated a significant difference between baseline and 60 minutes (p = 0.025) and between 60 
minutes and 120 minutes (p = 0.010) for VAS question two. No difference was found between 
baseline and 120 minutes (p = 0.362). There was a main effect of time for VAS question three (F 
= 12.557; p = 0.004). Post hoc analysis indicated a significant difference between baseline and 
60 minutes (p = 0.002), between 60 minutes and 120 minutes (p = 0.021), and baseline and 120 
minutes (p = 0.020) for VAS question three.  
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CHAPTER 5:  
DISCUSSION 
 The increased prevalence of T2DM in the United States prompted this study’s objective 
to evaluate the effect of an acute bout of exercise compared to no exercise in individuals at risk 
for developing T2DM. Our major finding was that there was no significant difference between 
the two conditions (exercise + rest) for both acylated ghrelin and GLP-1 concentrations. 
Additionally, there was no significant difference in AUC for both acylated ghrelin and GLP-1. 
An acute bout of aerobic exercise has only been shown to decrease levels of acylated ghrelin [23, 
24] without affecting total ghrelin [127, 129]. With this in mind, we measured acylated ghrelin 
compared to total ghrelin. However, it is likely that we did not see a difference due to the short 
duration of either the exercise bout or its frequency.  
Martins et al. (2010) studied the effects of a 12-week exercise program on hunger 
hormones, which resulted in a greater change and suppression of 1.5–2 hours postprandial 
acylated ghrelin compared to the control [135]. Broom et al. (2007) demonstrated that a 60-
minute bout of exercise had lower acylated ghrelin concentrations over three hours after exercise 
compared to the control trial [23]. These findings are similar to a subsequent study, which 
showed two trials, including 90-minutes of resistance training and a 60-minute run, both revealed 
decreased acylated ghrelin compared to the control [24]. Because these previous studies saw a 
suppression of acylated ghrelin during and after exercise, we expected to see an attenuation of 
acylated ghrelin after 15 minutes of walking. However, the acute bout of exercise in the present 
study may have been too short of duration to elicit a change in hormone levels.  
Perhaps, we did not see a significant change because the acute bout of exercise was at too 
low of an intensity to greatly affect hunger hormones. The acute bout of exercise of a 15-minute 
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self-selected walking pace was selected for easy adherence for sedentary individuals. However, 
this intensity was lower than those observed in previous studies that saw a change in hunger 
hormones. Deighton et al. (2013) showed evidence that supramaximal (~ 68% VO2max) exercise 
might elicit a more potent suppression of acylated ghrelin compared to vigorous endurance 
exercise [132]. Alternatively, other studies have shown that higher intensities have a greater 
affect [128]. King et al. (2010b) showed decreased acylated ghrelin levels after 90 minutes of 
exercise at subject’s 70% VO2max [128]. However, it is unlikely that obese or sedentary 
individuals would complete an exercise for the duration of 90 minutes or that they could 
maintain that high of an intensity. The self-selected walking pace was specifically chosen to 
stimulate adherence with minimal effort. Based on the average heart rates of individuals during 
our walking trial, the intensity was considered moderate (~ 61% age-predicted maximal heart 
rate).  
Moderate-intensity aerobic exercises has shown an increase in active GLP-1 
concentrations by 11–50% [26, 27] compared to the non-exercise controls. For example, Ueda et 
al. (2009a) determined that 30 minutes of aerobic exercise at 50% VO2max resulted in a 
significant increase in GLP-1 concentrations after exercise compared to the non-exercise control 
[26]. Similarly, Martins et al. (2007) revealed GLP-1 levels rose postprandially and mean values 
were significantly higher after a 60 minute bout of exercise at 65% maximal heart rate, compared 
to the non-exercise group [129]. Considering these findings, we wanted to determine if a single 
shorter bout of moderate-intensity exercise could elicit the same effect. Although, Chanoine et al. 
(2008) found that 1-hour of aerobic exercise seemed to have an increase in the acute response of 
GLP-1 to the test meal, we found contrasting results. One explanation for this result is the 
exercise frequency. In the study by Chanoine and colleagues, exercise trials included five 
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consecutive days of aerobic exercise, whereas the present study, included a single bout of 
exercise. Perhaps, the exercise consistency could have elicited a greater hormone response in the 
obese subjects compared to a single exercise bout. Also, their exercise trial lasted one hour 
compared to the 15-minute bout of exercise in our study, leading us to believe the duration had 
the highest impact. 
The demographic population used in this study may have influenced hunger hormones 
due to T2DM and obesity playing a role in blunted hormone levels. Previous research has shown 
an impairment in hunger hormones in the obese and diabetic populations [10]. For example, 
ghrelin levels are lower in obese subjects than in normal weight subjects [15]. Since obese 
subjects already have lower ghrelin levels, there is a chance we could not see a significant 
decrease in this population. It is possible that we may have seen an effect in a healthy population 
or with normal weight subjects like Vantansever-Ozen et al. (2011) demonstrated. They found 
that healthy men had significantly lower acylated ghrelin concentrations in the exercise trial 
compared to the control trial [133]. Similarly, Heden et al. (2013) found supporting evidence that 
normal weight subjects significantly reduced acylated ghrelin levels in the exercise trial 
compared to the control trial [137]. These studies revealed healthy subjects show greater 
hormone responses after a bout of exercise. However, we continued with the obese population 
because individuals at risk for metabolic diseases including T2DM, need an intervention to 
prevent, or at least prolong chronic disease.  
For time, there was a significant difference between 0 and 60 minutes in acylated ghrelin. 
In all subjects, acylated ghrelin decreased significantly from 0 to 60 minutes. This is most likely 
the result of eating a meal at the beginning of the two-hour time period, as ghrelin is known to 
increase before a meal and decrease postprandially following a normal diurnal variation [15, 40]. 
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Fasting causes an elevation of ghrelin levels in which levels decrease immediately following 
food intake with postprandial levels suppressed for up to 60–120 minutes after ingestion [53]. 
Therefore, we cannot conclude that the decrease in ghrelin was a result of exercise only. 
Composition of a meal has a strong influence on concentrations of ghrelin [42]. Previous 
research has shown that ingested lipids suppress ghrelin less effectively than carbohydrates or 
proteins [156]. It is possible that if our test meal was high in fat to elicit a lipid response, we may 
not have seen a decline in ghrelin levels. Therefore, since our test meal was high in 
carbohydrates, it was adequately designed to assess ghrelin, although we did not see a difference 
between trials. For example, Nedvidkova et al. (2003) found that women who consumed a high-
carbohydrate diet showed a larger drop in ghrelin levels than women who consumed a high-fat 
diet [62]. Considering our test meal was composed of 70% carbohydrates, this could have had a 
suppressing effect on acylated ghrelin from baseline to 60 minutes.  
Although the mechanism of GLP-1 as a satiety hormone is not completely understood, 
we know that it promotes satiety induction through nutrient sensing in the lower intestine. GLP-1 
is released postprandially into circulation in proportion to the calories ingested [77]. GLP-1 is 
released by various stimuli including glucose, fats, and proteins. In humans, GLP-1 levels 
increase postprandially and generally peak within one hour then gradually decrease to basal 
levels [68]. We found a significant difference in GLP-1 concentrations between 0 and 60 
minutes. In all subjects, GLP-1 increased significantly from 0 to 60 minutes. This is likely the 
cause of satiety increasing postprandially due to the normal diurnal pattern. A study by Adam 
and Wererterp-Plantenga (2007) analyzed levels of GLP-1 in a group of overweight/obese adults 
and found that preprandial levels were similar in overweight/obese adults compared with normal-
weight controls. However, the postprandial GLP-1 response was significantly blunted 30 minutes 
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after a test meal compared to the control subjects [14]. Because of this, it is possible that our 
subjects had a blunted GLP-1 response that we missed, prompting a lower concentration of GLP-
1 postprandially. Again, because hunger hormones are altered postprandially, we cannot 
conclude that GLP-1 concentrations responded only to exercise. 
Perceived hunger determined using the VAS questionnaire had no correlation to the 
biological markers, acylated ghrelin and GLP-1. Multiple studies have used VAS questionnaires 
to assess perceived hunger. Vantansever-Ozen et al. (2011) assessed hunger on one end (0 mm) 
of the line with the descriptor “not at all hungry” while on the other extreme (100 mm) was the 
descriptor “totally hungry”. Although we used the same question and descriptors in this study, 
Vantansever-Ozen found a significant correlation between acylated ghrelin and hunger after 120 
minutes of exercise, while we did not. Perhaps we did not see a correlation due to the exercise 
protocol and duration. The intensity of exercise in the previous study included 50–70% VO2max 
running, which could have produced greater suppression on ghrelin levels. If ghrelin levels are 
further suppressed, perceived hunger should be suppressed as well. Since we determined 15 
minutes of moderate intensity walking is an insufficient duration to lower acylated ghrelin levels, 
we should expect that perceived hunger would also be unaffected. Hagobian et al. (2013) found 
hunger was significantly lower and fullness was significantly higher after their buffet meal in 
both exercise and rest conditions [123]. This is most likely due to the self-selection of food 
consumed at a buffet meal. Unlike a buffet meal, our test meal was predetermined. Since our 
subjects could not select their own meal, it is difficult to say they were fully satisfied by the food 
given. This could result in an alteration on their hunger and fullness perception. Similar to our 
findings, Hagobian et al. (2013) found that appetite hormones and appetite rating were weak and 
nonsignificant. Additionally, Heden et al. (2013) also found that fasting perceived hunger was 
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not significant between trials [137]. Although, there was no correlations in our study, we found a 
main effect for time, which has also been seen in previous research. Broom et al. (2007) found a 
main effect for time in hunger, showing a decrease in hunger after the test meal for three hours 
[23]. Prado et al. (2014) also demonstrated that hunger scores increased greatly in both exercise 
and conditions from baseline to 150 minutes [147].   
Strengths 
This study has many strengths. First, a repeated measures crossover design where each 
subject served as his or her own control for each treatment was utilized. This specific design 
prompted not only a valid and reliable study, but reduced the risk of error. Secondly, subject 
meals were standardized 24 hours prior to each visit, eliminating any significant differences in 
dietary composition between conditions. This decreased the impact that external factors might 
have on our findings. Lastly, this is the only study to our knowledge that has looked at a short 
bout of exercise on hunger hormones in a prediabetic population. Since this population is at a 
higher risk for T2DM and cardiovascular disease, identifying the impact of preventive strategies 
on regulating hunger hormones is important yet understudied.  
Limitations  
This study has some limitations. Physical activity prior to testing visits was not measured 
which could have a potential effect on hormone levels. As found in Heden et al. (2013), exercise 
the night before a meal suppresses acylated ghrelin concentrations. However, we specifically 
chose a sedentary group of individuals and asked subjects to refrain from any form of exercise at 
least 24 hours prior to visits to eliminate variations in activity. Secondly, many studies have 
measured hormone levels more frequently [127, 137, 142]. However, due to cost, we could not 
have blood draws as frequently as desired. We decided to drop the 30-minute measure since 
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GLP-1 peaks from 1–2 hours and postprandial acylated ghrelin levels are elevated 60–120 
minutes after ingestion [53]. Finally, samples according to the assay procedures should have 
been immediately placed in a refrigerated centrifuge. This was problematic because the wet lab 
and exercise physiology lab are located in two separate buildings, therefore; the proximity could 
have affected the integrity of the samples. However, all blood samples were kept in a cooler to 
maintain temperature during transit and every effort was made to get the samples into the 
refrigerated centrifuge as quickly as possible. 
Future Directions  
Future studies should utilize different exercise intensities and durations within a similar 
protocol in the prediabetic population to assess the effects of various exercise modalities on 
hunger regulation. It would be beneficial to look at an exercise bout 60-120 minutes 
postprandially to see if exercise can influence hormone levels when the normal diurnal pattern 
shows ghrelin typically starts to raise again in preparation for the next meal. Also, with a similar 
protocol, future studies should aim to collect blood draws more frequently to see changes we 
could have missed. Finally, future research should consider including multiple populations 
within the same protocol. For example, include healthy individuals, prediabetics, and T2DM 
subjects to see how postprandial exercise affects each of these populations differently. From 
there, researchers could get a better idea of what prevention strategies are best to target each 
population.  
Conclusion 
 This study showed that a 15-minute walk performed shortly after a meal does not have a 
significant impact on hunger hormones including acylated ghrelin and active GLP-1 
concentrations in individuals at risk for T2DM. 
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The	Nutrition	Program	at	UNLV	is	recruiting	non-smoking,	sedentary	
adults	(45-69	years	of	age)	who	are	free	of	chronic	disease.	
The	purpose	of	this	research	study	is	to	examine	whether	a	postmeal	walk	can	
influence	the	metabolic	impact	of	a	typical	American	diet.	
Participation	will	include:	
Ø An	initial	screening	visit	and	2	testing	visits	at	the	UNLV	exercise	physiology	
lab	
Ø 4	days	of	prepared	meals	before	and	after	2	testing	visits	
Ø Providing	blood	samples		
Ø Body	composition	testing		
Ø Personalized	Nutrition	Assessment		
Ø Incentives	of	$100	dollars	
INTERESTED?	PLEASE	FILL	OUT	A	SHORT	SURVEY	AND	WE’LL	CONTACT	YOU!	https://www.surveymonkey.com/r/NQGN3RT	
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _	
MEAL TIME WALKING TRIAL 
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Qualifications: 
Ø Non-smoking, sedentary 
Ø Ages 45-69 years old 
Ø Must be free of chronic disease, weight stable in past 3 months, not 
pregnant or planning on becoming pregnant 
Participation will include: 
Ø An initial screening visit and 2 testing visits at the UNLV exercise 
physiology lab 
Ø Body composition testing 
Ø 4 days of prepared meals before and after 2 testing visits 
Ø Willingness to follow study protocol: providing blood samples, wearing 
glucose meter, eating test meals, walking on treadmill and staying on 
test site for max of 3 hours each visit 
Ø Personalized Nutrition Assessment 
Ø Incentives of $100 dollars 
INTERESTED??  Please visit our recruitment site: 
https://www.surveymonkey.com/r/NQGN3RT	
The UNLV NUTRITION PROGRAM IS RECRUITING NON-
SMOKING, SEDENTARY ADULTS (45-69 YEARS OF AGE) WHO 
MAY BE AT RISK FOR DIABETES (BMI of 25-40 kg/m2). THIS 
STUDY WILL EXAMINE WHETHER A 15-MINUTE POSTMEAL 
WALK REDUCES THE METABOLIC IMPACT OF A STANDARD 
AMERICAN MEAL.
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Adults Needed for UNLV Mealtime Walking Study 
The UNLV Nutrition Program is recruiting non-smoking, sedentary adults 
for a research trial. This 2-week research study is to examine whether a 
postmeal walk can influence the metabolic impact of a typical American 
diet. Your commitment will consist of an initial screening visit and two 
testing days. Incentives will be provided during the study, totaling $100 
dollars, as well as access to individual lab results following completion of 
the study, including an explanation of the findings. 
 
For more information or to apply for the study, please visit our 
recruitment site: 
https://www.surveymonkey.com/r/NQGN3RT	
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By completing this survey, you are consenting to provide us with these data as part of a research 
study. The purpose of this study is to evaluate the effect of postmeal walking on 24-hour glucose 
control in individuals at risk for diabetes. Consent for this study is a 2-step process. The initial 
consent is a series of preliminary questions contained within this survey. If eligible, you will then 
be asked to further participate in the study and come to the Kinesiology laboratory at UNLV to 
complete the final consent. Participation in this survey is voluntary and you may exit the survey 
at any time. 
 
1. Please provide your e-mail address: 
2. What is your height and approximate weight? 
3. Are you between the ages of 45 and 69 years old? 
4. Are you healthy and free of chronic disease? 
5. Are you able and willing to walk on a treadmill at a brisk pace (~3mph) for 15 minutes? 
6. Do you have any food allergies? 
7. Would you be willing and able to visit the UNLV campus for 3 study visits, spaced 1 
week apart for this study? (The first visit will take ~60 min and 2 & 3 will take ~2.5 
hours). 
8. Are you ok providing blood sample via a fingerstick? 
9. Are you willing to eat the provided standardized meals on test days? 
10. If female, do you still have a menstrual cycle? 
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HEALTH HISTORY QUESTIONNAIRE                                ID#___________________ 
 
1. Gender:  M    F 
 
2. Age:  __________ 
 
3. Have you lost or gained more than 10 lbs in the last 12 months?         Yes         No 
     If yes, how much lost or gained? _________     How long ago? ___________ 
 
4. Ethnicity: (please circle)  Native American     African-American     Caucasian     Hispanic     
Asian     Other 
 
5. Do you smoke?  No, never ________   
                   Yes _______     # Cigarettes per day = ________                               
                               I used to, but I quit _______ months/years (circle) ago 
 
6. Have you ever been pregnant? ___________________ 
 If yes, date of last pregnancy? ___________ 
 
7. What were the dates of your last menstrual cycle? ________________________ 
 
8.  Do you take any medications regularly?     Yes No           If yes, list type and frequency: 
     
Medication    Dosage    Frequency 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
 
9. Do you currently take supplements (vitamins, minerals, herbs, etc.)?    Yes    No         If yes, 
list type and frequency:                               
     
Supplement    Dosage    Frequency 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________  
 
 
10.  Have you ever been hospitalized?  Yes    No         If yes, for what? 
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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11. Please ANSWER (YES/NO) if you currently have or if you have ever been clinically 
diagnosed with any of the following diseases or symptoms: 
 
 YES NO  YES NO 
Coronary Heart Disease   Chest Pain   
High Blood Pressure   Shortness of Breath   
Heart Murmur   Heart Palpitations   
Rheumatic Fever   Any Heart Problems   
Irregular Heart Beat   Coughing of Blood   
Varicose Veins   Feeling Faint or Dizzy   
Stroke   Lung Disease   
Diabetes   Liver Disease   
Low Blood Sugar   Kidney Disease   
Bronchial Asthma   Thyroid Disease   
Hay Fever   Anemia   
Leg or Ankle Swelling   Hormone Imbalances   
Eating Disorder   Depression   
 
Please elaborate on any condition listed above. 
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________ 
 
 
12.  How would you rate your lifestyle? 
Not active ___________       Active ___________ 
Somewhat active __________      Very Active ___________ 
 
13. Please circle the total time you spend in each category for an average week. 
  
Light activities such as: 
 Slow walking, golf, slow cycling, doubles tennis, easy swimming, gardening 
 Hours per week:     0  1  2  3  4  5  6  7  8  9  10+ 
  
Moderate activities such as: 
Mod. Moderate walking, cycling, singles tennis, moderate swimming, weight 
lifting 
 Hours per week:     0  1  2  3  4  5  6  7  8  9  10+ 
  
Vigorous activities such as: 
Fast walking/jogging, fast cycling, court sports, fast swimming, heavy/intense 
weight lifting 
                   Hours per week:     0  1  2  3  4  5  6  7  8  9  10+ 
 
14.  How much alcohol do you drink? (average drinks per week)  ___________ 
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15.  Do you have any food allergies?     Yes    No       If yes, 
explain:________________________________________ 
 
 
16. The test shake contains dairy and gluten. Is this a problem?   Yes    No       If yes, 
explain:________________________________________ 
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Physical Activity Readiness Questionnaire (PAR-Q) and You  
Regular physical activity is fun and healthy, and increasingly more people are starting to 
become more active every day. Being more active is very safe for most people. However, some 
people should check with their doctor before they start becoming much more physically active.  
If you are planning to become much more physically active than you are now, start by 
answering the seven questions in the box below. If you are between the ages of 15 and 69, the 
PAR-Q will tell you if you should check with your doctor before you start. If you are over 69 
years of age, and you are not used to being very active, check with your doctor.  
 Common sense is your best guide when you answer these questions. Please read 
the questions carefully and answer each one honestly:  
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Visual Analog Scale (VAS) 
 
Please mark a vertical line at the point on the lines below where you feel best represents your 
current state of hunger.  
 
1. How hungry do you feel?  
 
______________________________________________  
                    Not at all hungry           Totally hungry 
 
2. How satisfied do you feel?  
 
______________________________________________  
   Completely satisfied           Not at all satisfied  
 
3. How full do you feel? 
 
______________________________________________ 
            I can’t eat another bite           Empty 
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INFORMED CONSENT  
Department of Kinesiology and Nutrition Sciences 
   
TITLE OF STUDY: Effects of Postmeal Walking on 24-hour Glucose Control 
INVESTIGATOR(S): Jessica Knurick, PhD 
For questions or concerns about the study, you may contact Jessica Knurick at 
Jessica.knurick@unlv.edu or 702-895-1453.   
 
For questions regarding the rights of research subjects, any complaints or comments regarding 
the manner in which the study is being conducted, contact the UNLV Office of Research 
Integrity – Human Subjects at 702-895-2794, toll free at 877-895-2794 or via email at 
IRB@unlv.edu. 
   
 
Purpose of the Study 
You are invited to participate in a research study.  The purpose of this study is to evaluate the effect 
of postmeal walking on 24 hour glucose control in individuals at risk for diabetes. 
 
Participants 
You are being asked to participate in the study because you fit these criteria: you have indicated 
to us that you are 45-69 years of age, generally sedentary, and do not smoke. If female, you have 
no possibility of being pregnant and no longer have a menstrual cycle. You have not been 
diagnosed with a chronic disease, including diabetes and you are free from unresolved medical 
conditions. You have been weight stable (+/- 3kg) in the past 3 months and you are able to walk 
on a treadmill at a moderate pace (~3.5 mph). Finally, you are willing to follow the study 
protocol including: eating test meals, providing blood, wearing the 24-hour glucose meter for 
~60 hours, staying at the test site for 2.5 hours each visit, and completing short surveys. 
 
Procedures 
If you volunteer to participate in this study, you will be asked to do the following: 
 
This study will initially involve the completion of brief demographic and health history 
questionnaires to demonstrate the absence of conditions that may affect health and blood 
assessments. This research entails that you visit our test facility on two additional occasions. At 
each of these occasions you will consume a test meal (bagel and apple juice), and provide venous 
blood samples. 
 
At the first lab visit, you will be asked to complete a questionnaire about your general health. A 
fasting pre-screen blood sample from a finger prick will be obtained to determine inclusion in the 
study. Your height, bodyweight, waist circumference, and blood pressure will be measured. In 
addition, body composition will be measured using an InBody scale. This scale uses a 
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‘bioelectric impedance’ approach – it sends a small electronic current through you. You will not 
feel anything and this takes only about 3-minutes. Lastly, you will be asked to walk across a 
short measured area to assess preferred walking speed. This visit will last ~45 minutes. Two 
additional visits will be scheduled based on availability. 
 
For the remaining 2 visits (~2.5 hours/visit) you will be asked to fast (no food or drink with the 
exception of water in the preceding 12 hours). You will also be instructed not to exercise the day 
prior to each visit and to consume standardized meals the day before and of testing, which will 
be prepared by our nutrition staff. The test meal will be consumed within 15 minutes of arrival. 
The two visits will be spaced approximately one week apart. At these visits you will consume the 
test meal with or without a postmeal treadmill walk. During the treadmill walk, we will record 
heart rate data from a monitor placed around the upper abdomen.  For each session, a fasting 
blood sample will be obtained for determination of basal concentrations of blood glucose. You 
will then be given 15 minutes to eat a standardized meal (bagel and apple juice). Venous blood 
samples will be collected prior to meal ingestion and at 15, 30, 60, and 180 minutes post meal. 
 
Approximately 36 hours prior to testing, you will be asked to wear a continuous glucose monitor, 
which will measure your blood sugar for the subsequent 60 hours. The glucometer will be placed 
on your lower abdomen and will require a single needle insertion. After this time period, you will 
be asked to return to the lab, so that we are able to remove the glucometer.  
 
Benefits of Participation  
There will not be direct benefits to you as a participant in this study. However, you will be 
provided with all your health marker test results if desired including your body fat composition, 
and fasting blood glucose concentrations. You will have the opportunity to attend a free healthy 
living strategies class after study completion offered by a registered dietitian.  
 
Risks of Participation  
There are risks involved in all research studies. This study may include only minimal risks. A 
trained researcher will perform glucose draws via fingerstick under standard and sterile 
conditions, but temporary bruising of the skin or a feeling of faintness is possible at the time of 
the blood draw. For the blood pressure tests, a squeezing pressure will be applied to the upper 
arm for a short time. The test meal is a bagel and juice and contains gluten, which is unsuitable 
for individuals who have gluten intolerance. Treadmill walking will be at low-moderate intensity 
(2.5-3.0 mph) pace under the supervision of a trained exercise physiologist. We will ask that you 
bring appropriate walking shoes to this visit. You are asked to tell investigators to stop any 
testing at any time if desired.  
 
Cost /Compensation  
There may be financial cost to you to participate in this study related to time and travel. The 
study will take approximately 6 total hours of your time. Participants will receive cash incentives 
$50 at lab visit 2 and $50 at lab visit 3 to offset some of these costs.  
 
Confidentiality  
All information gathered in this study will be kept as confidential as possible.  No reference will 
be made in written or oral materials that could link you to this study.  All deidentified records 
will be stored in a locked facility at UNLV for up to 10 years after completion of the study. 
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Blood samples will be identified only by the subject number and date and stored in freezers in 
the Nutrition labs at the BHS building for up to 5 years. Only the study investigators and the 
laboratory staff will access these samples. After the storage time the information gathered will be 
destroyed.  
 
Voluntary Participation  
Your participation in this study is voluntary. You may refuse to participate in this study or in any 
part of this study.  You may withdraw at any time without prejudice to your relations with 
UNLV. You are encouraged to ask questions about this study at the beginning or any time during 
the research study.  
 
Participant Consent:  
I have read the above information and agree to participate in this study.  I have been able to ask 
questions about the research study.  I am at least 18 years of age.  A copy of this form has been 
given to me. 
 
 
 
             
Signature of Participant                                             Date  
 
        
Participant Name (Please Print)                                               
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UNLV Biomedical IRB - Expedited Review 
Approval Notice 
 
DATE: October 19, 2016 
 
TO: Jessica Knurick, PhD 
FROM: UNLV Biomedical IRB 
 
PROTOCOL TITLE: [869576-3] Effects of Postmeal Walking on 24-hour Glucose Control 
SUBMISSION TYPE: Revision 
 
ACTION: APPROVED 
APPROVAL DATE: October 19, 2016 
EXPIRATION DATE: October 18, 2017 
REVIEW TYPE: Expedited Review 
 
Thank you for submission of Revision materials for this protocol. The UNLV Biomedical IRB has 
APPROVED your submission. This approval is based on an appropriate risk/benefit ratio and a protocol 
design wherein the risks have been minimized. All research must be conducted in accordance with this 
approved submission. 
 
PLEASE NOTE: 
Upon approval, the research team is responsible for conducting the research as stated in the protocol most 
recently reviewed and approved by the IRB, which shall include using the most recently submitted Informed 
Consent/Assent forms and recruitment materials. The official versions of these forms are indicated by footer 
which contains approval and expiration dates. If your project involves paying research participants, it is 
recommended to contact Carisa Shaffer, ORI Program Coordinator at (702) 895-2794 to ensure compliance 
with subject payment policy. 
 
Should there be any change to the protocol, it will be necessary to submit a Modification Form through 
ORI - Human Subjects. No changes may be made to the existing protocol until modifications have been 
approved. 
 
ALL UNANTICIPATED PROBLEMS involving risk to subjects or others and SERIOUS and UNEXPECTED 
adverse events must be reported promptly to this office. Please use the appropriate reporting forms for this 
procedure. All FDA and sponsor reporting requirements should also be followed. 
 
All NONCOMPLIANCE issues or COMPLAINTS regarding this protocol must be reported promptly to this 
office. 
 
This protocol has been determined to be a Minimal Risk protocol. Based on the risks, this protocol requires 
continuing review by this committee on an annual basis. Submission of the Continuing Review Request 
Form must be received with sufficient time for review and continued approval before the expiration date of 
October 18, 2017. 
 
If you have questions, please contact the Office of Research Integrity - Human Subjects at IRB@unlv.edu or 
call 702-895-2794. Please include your protocol title and IRBNet ID in all correspondence. 
Office of Research Integrity - Human Subjects 
4505 Maryland Parkway . Box 451047 . Las Vegas, Nevada 89154-1047 
(702) 895-2794 . FAX: (702) 895-0805 . IRB@unlv.edu 
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Modification Request Form 
Instructions: 
1. Complete all sections of this form. 
2. Submit all previously submitted documents that contain information affected by the 
modification(s). 
  
Note: 
1. Handwritten and hand delivered forms will not be accepted. 
2. INCOMPLETE FORMS WILL BE RETURNED. 
3. Modification may not be implemented until you have received notification of IRB approval. 
4. For your records, it is important that you keep a copy of this completed form. 
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